P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

March 2014

Features

Major Changes for Part D Drug Plans Scheduled for 2015

Health Plans and PBMs Would Be the Chief Beneficiaries

Medicare is proposing significant revisions to its Part D drug program. The biggest change: the elimination of antidepressants and immunosuppressants as “protected classes” on formularies in 2015 and the removal of antipsychotics in 2016.
Stephen Barlas

Retrospective Analysis of Azithromycin Versus Fluoroquinolones for the Treatment of Legionella Pneumonia

A single-center retrospective study that compared clinical outcomes of patients with Legionella pneumonia treated with azithromycin versus fluoroquinolones for more than 12 years found that azithromycin appears to have clinical efficacy similar to fluoroquinolones.
Jerod L. Nagel, PharmD; Rachel E. Rarus, PharmD; Alex W. Crowley, PharmD; and Cesar Alaniz, PharmD

Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer

Overexpression of human epidermal growth factor receptor 2 (HER2) is an important factor in cancer survival, proliferation, and metastasis. Agents that target HER2-positive tumors are used with traditional chemotherapies, with other targeted therapies, or as monotherapy to treat metastatic breast cancers.
Maribeth Maher

P&T Snapshot

Breast Cancer by the Numbers

The American Cancer Society estimates that 40,000 women will die from breast cancer this year. But thanks to steady progress in the war on cancer, millions of U.S. women with a history of the disease are alive today. Key statistics on survival rates, therapies in use, and treatment costs are provided.

Departments

Medication Errors

Electronic Prescribing Vulnerabilities: Height and Weight Mix-Up Leads to Dosing Error

Height and weight errors confound electronic prescribing.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Manufacturers and Hospitals Spar Over Drug Shortage Reporting

FDA Proposal Seeks to Improve Early Warning System

Stephen Barlas

Pharmaceutical Approval Update

Dapaglifozin (Farxiga) for improved glycemic control in type-2 diabetes, and trametinib (Mekinist) in combination with dabrafenib (Tafinlar) for the treatment of advanced, unresectable melanoma
Marvin M. Goldenberg, PhD, RPh, MS

New Drugs/Drug News/New Medical Devices

Drug Forecast

Alogliptin (Nesina) for Adults with Type-2 Diabetes

Laura Dineen, Connie Law, Rebecca Scher, and Eunice Pyon, BS, PharmD